

## Mirena® (levonorgestrel-releasing intrauterine system) – Expanded indication

- On August 11, 2021, the <u>FDA approved</u> Bayer's <u>Mirena (levonorgestrel-releasing intrauterine</u> system), for prevention of pregnancy for up to 7 years; replace after the end of the seventh year.
  - Previously, Mirena was approved for prevention of pregnancy for up to 6 years.
- Mirena is also approved for the treatment of heavy menstrual bleeding for up to 5 years in women
  who choose to use intrauterine contraception as their method of contraception; replace after the end
  of the fifth year if continued treatment of heavy menstrual bleeding is needed.
- The approval of Mirena for the expanded indication was based on the Mirena Extension Trial, an open-label, uncontrolled study enrolling 362 women. The pregnancy rate calculated as the Pearl Index (PI) was the primary efficacy endpoint used to assess contraceptive efficacy. The PI was based on 28-day equivalent exposure cycles; evaluable cycles excluded those in which back-up contraception was used unless a pregnancy occurred in that cycle. The cumulative 2-year pregnancy rate for Years 6 and 7 was estimated by the Kaplan-Meier method.
  - Based on 2 pregnancies (1 in Year 6 and 1 in Year 7) and 7,269 exposure cycles, the cumulative pregnancy rate at the end of the 2 year period of extended use (Years 6 and 7) was 0.71% with a 95% upper confidence limit of 2.84%.
- For contraception, Mirena should be removed by the end of the seventh year and replaced at the time of removal with a new Mirena if continued use is desired.
  - Mirena contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to approximately 10 mcg/day after 5 years and 8 mcg/day after 7 years.
  - Mirena should be inserted by a trained healthcare provider.
  - Refer to Mirena's drug label for dosing for treatment of heavy menstrual bleeding.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.